ResearchCLINICALTRIALSApr 17
Researchers completed a study that collected information about how Canavan disease develops and progresses in children. The study looked at medical records from 67 patients and also gathered new information about their movement abilities and important health milestones. This type of study helps doctors understand the disease better and can guide future treatment development.
WHY IT MATTERSThis completed natural history study provides detailed data on how Canavan disease progresses in children, which is essential for designing future clinical trials and understanding what to expect from the disease.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new gene therapy called SPK-10001 to treat Huntington's disease, a rare brain disorder that causes movement problems and cognitive decline. This early-stage study will check if the treatment is safe and whether it helps patients. About 53 people with Huntington's disease will participate in this trial, which is being run by Roche, a major pharmaceutical company.
WHY IT MATTERSThis is one of the first human trials of SPK-10001, a gene therapy specifically designed to target the genetic cause of Huntington's disease, offering hope for a disease that currently has no cure.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new gene therapy called BBP-812 to treat Canavan disease, a rare brain disorder that affects children. The therapy uses a modified virus to deliver a healthy copy of a gene that's missing or broken in people with this disease. This early-stage trial will check if the treatment is safe and whether it helps patients.
WHY IT MATTERSThis trial is now actively recruiting children with Canavan disease — if your child has been diagnosed, you may be eligible to participate in one of the first human tests of this gene therapy approach.
Clinical trialCLINICALTRIALSApr 17
Researchers are testing a new treatment called IFx-Hu2.0 combined with a cancer drug called pembrolizumab for people with Merkel cell carcinoma, a rare and aggressive skin cancer. In this study, some patients will receive the new treatment while others receive a placebo (fake treatment) to see which works better. The trial is looking for 118 adults to participate and is currently accepting new patients.
WHY IT MATTERSThis is the first Phase 2/3 trial testing IFx-Hu2.0 as an add-on therapy for Merkel cell carcinoma, offering checkpoint inhibitor-naïve patients a potential new treatment option beyond standard pembrolizumab alone.
ResearchPUBMEDApr 17
Researchers in Saudi Arabia studied how different factors affect the stress and well-being of parents who have children with three rare genetic diseases: cystic fibrosis, congenital adrenal hyperplasia, and Duchenne muscular dystrophy. They surveyed 107 parents and found that things like whether parents work, family income, and cultural factors all play a role in how well parents cope with having a sick child. Understanding these factors can help doctors and support services better help families dealing with rare diseases.
WHY IT MATTERSIf you're a parent of a child with CF, CAH, or DMD, this research identifies specific factors affecting your quality of life—such as employment status and family support—that healthcare providers can now address to improve your family's well-being.
ResearchBIORXIVApr 17
Scientists created OpenScientist, a new artificial intelligence tool that can help researchers discover medical breakthroughs faster. This AI assistant can read through lots of medical information, analyze data, and put together what it learns — tasks that normally take human scientists a long time. The goal is to speed up finding new treatments and understanding diseases better.
WHY IT MATTERSThis AI tool could help researchers discover new treatments and understand rare diseases more quickly by automating time-consuming research tasks, potentially leading to faster development of therapies for patients with rare conditions.
ResearchBIORXIVApr 17
Scientists are testing a new way to understand how genes cause diseases by combining two different research methods: one that studies genes in large groups of people, and another that looks at individual cells in the lab. This study checks whether both methods give the same answers, which would help researchers trust their findings more and move treatments from the lab to real patients faster.
WHY IT MATTERSIf validated, this approach could accelerate how researchers identify disease-causing genes in rheumatologic conditions, potentially leading to faster development of targeted treatments for patients with autoimmune and inflammatory diseases.
PolicyRSSApr 16
The FDA is inviting companies that make testosterone replacement therapy drugs to apply for approval of a new use: treating low sex drive in men with a specific condition called idiopathic hypogonadism (when the body doesn't make enough testosterone for unknown reasons). This is an early step that could lead to new treatment options for men with this condition.
WHY IT MATTERSMen with idiopathic hypogonadism who experience low libido may soon have an FDA-approved treatment option specifically designed for this symptom, rather than relying on off-label use of existing testosterone therapies.
ResearchBIORXIVApr 16
Researchers found that a protein called DDR2 is overactive in Alzheimer's disease and may be blocking the brain's natural cleaning system. They developed an antibody (a type of immune protein) that can cross into the brain and reduce DDR2 levels, which in early studies helped restore the brain's ability to clear out harmful waste products and improved Alzheimer's symptoms in animal models.
WHY IT MATTERSThis research identifies a new therapeutic target for Alzheimer's disease that works through a different mechanism than current treatments, potentially offering hope for patients whose disease progresses despite existing amyloid-targeting therapies.
ResearchPUBMEDApr 16
Scientists created a new tool called STRIPE that uses advanced genetic testing to read long strands of RNA (the instructions cells use to make proteins). This tool can detect genetic mistakes that cause rare diseases by looking at how genes are actually working in cells, not just finding the mutations themselves. It's designed to be faster, cheaper, and more practical than older methods, which could help doctors diagnose rare genetic diseases that are hard to identify.
WHY IT MATTERSPatients with undiagnosed rare genetic diseases could finally get answers through more accurate genetic testing, since STRIPE can detect disease-causing variants that standard DNA tests might miss.
Clinical trialCLINICALTRIALSApr 15
Researchers are testing a new AI-powered tool called IntelliWell that can find sperm cells in testicular tissue samples that appeared to have no sperm when checked the traditional way. If the tool successfully finds sperm, those cells could be used to help men with infertility have biological children through a procedure called ICSI. The study is enrolling 20 participants at Brigham and Women's Hospital.
WHY IT MATTERSFor men with azoospermia (no sperm in ejaculate) who were told their testicular tissue had no usable sperm, this AI tool could recover sperm that was missed by standard testing, potentially making fertility treatment possible when it seemed impossible before.
Clinical trialCLINICALTRIALSApr 15
Researchers are looking for 300 patients with Duchenne muscular dystrophy (DMD) to join a study about a medicine called givinostat. The study will track how safe the medicine is and how well it works for patients who are just starting to take it or have been taking it for less than 6 months. Patients will be followed for at least 2 years, with some being tracked for up to 5 years total.
WHY IT MATTERSThis real-world study will show how givinostat actually performs in everyday clinical practice for DMD patients in the US, providing practical safety and effectiveness data beyond what controlled trials reveal.
Clinical trialCLINICALTRIALSApr 15
Researchers are testing a cancer drug called nivolumab in patients with rare tumors that have a specific marker called PD-L1. This is a Phase 2 trial that will include up to 28 patients with many different types of rare cancers who haven't responded well to standard treatments. The study will last up to 12 months and measure how well the drug works.
WHY IT MATTERSIf you have one of the 43 rare tumor types listed and your cancer has high PD-L1 expression, this trial offers access to an immunotherapy that may work regardless of where your cancer started.
Clinical trialUNITERAREApr 15
Researchers are looking for pregnant women with NMOSD (a rare disease that affects the nerves in the eyes and spinal cord) who have taken or are taking a medicine called UPLIZNA to join a safety study. The study will track what happens to these women and their babies to make sure the medicine is safe during pregnancy. This information will help doctors understand whether UPLIZNA can be used safely by pregnant patients with NMOSD.
WHY IT MATTERSThis trial is recruiting pregnant women with NMOSD who have been exposed to UPLIZNA — currently there is limited safety data on this drug during pregnancy, so this study directly addresses a critical gap for women of childbearing age managing this serious neurological condition.
Clinical trialUNITERAREApr 15
Researchers are testing a new imaging scan called 18F-mFBG that can take pictures of the heart in people with Lewy body dementia, a brain disease that causes movement problems and thinking difficulties. This Phase 2 trial is now accepting patients and aims to see if this special scan can help doctors better understand and diagnose the disease. The scan uses a safe radioactive tracer that shows how well the heart's nerve endings are working.
WHY IT MATTERSThis trial is now actively recruiting patients with Lewy body dementia — if you have this diagnosis, you may be eligible to participate in a study that could help develop better diagnostic tools for your condition.
Clinical trialUNITERAREApr 15
Researchers are looking for patients with a specific type of blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia to test a new treatment combination. The treatment uses chemotherapy drugs (EPOCH), sometimes combined with rituximab (a protein therapy), plus a targeted drug called ponatinib. This is a Phase 2 trial, meaning it's testing whether the treatment works and is safe in a larger group of patients.
WHY IT MATTERSThis trial is now actively recruiting patients with newly-diagnosed Ph+ ALL/lymphoma and offers access to ponatinib, a third-generation tyrosine kinase inhibitor that may improve outcomes for this aggressive blood cancer.
Clinical trialUNITERAREApr 15
Researchers are testing a new cancer treatment that combines two approaches: a chemotherapy drug called temozolomide and a vaccine called SurVaxM that trains the immune system to fight cancer cells. This trial is for patients with neuroendocrine carcinomas (rare cancers in hormone-producing cells) that are spreading and getting worse despite other treatments. The study is now accepting patients and will run through 2026.
WHY IT MATTERSThis is one of the first trials testing an immunotherapy vaccine specifically for metastatic neuroendocrine carcinomas, offering a potential new option for patients whose cancer has progressed on standard treatments.
PolicyRSSApr 14
The FDA released new guidelines to help companies develop gene therapy treatments that use genome editing—a technology that can fix or change faulty genes. These guidelines explain what safety information and testing companies need to provide before the FDA will approve their treatments. This is meant to make it clearer and faster for companies to develop new gene therapies for patients with genetic diseases.
WHY IT MATTERSThis guidance establishes the regulatory pathway that will determine which genome editing therapies can reach patients, potentially accelerating approval timelines for rare genetic diseases currently lacking treatment options.
Clinical trialCLINICALTRIALSApr 14
Researchers are looking for young adults ages 15-25 with rare genetic disabilities to join a study about getting jobs and education. The study will follow 300 participants and examine the challenges these young people face when trying to go to school, get internships, or find work. Many young people with rare genetic diseases struggle with these opportunities because of their condition and lack of support.
WHY IT MATTERSThis trial directly addresses employment and education barriers that young adults with rare genetic disabilities face — areas where they typically have the fewest resources and support.
Clinical trialCLINICALTRIALSApr 14
Researchers tested a new gene therapy called ST-920 for Fabry disease in 36 patients. This treatment uses a modified virus to deliver instructions that help the body make an enzyme called alpha-galactosidase A, which people with Fabry disease don't produce enough of. The trial is now complete and tested whether different doses were safe and well-tolerated.
WHY IT MATTERSThis completed Phase 1/2 trial is the first human test of ST-920, meaning results could help determine if gene therapy can provide long-term relief for Fabry disease patients who currently require lifelong enzyme replacement infusions.